Skip to main content

Bristol-Myers Squibb to Highlight SQI’s Technology at WRIB Conference

By November 25, 2020No Comments

SQI’s Strength in Immunogenicity Testing Featured In Multiple PresentationsToronto, OntarioApril 9, 2015SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD; OTCQX: SQIDF),

a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics (“SQI”), today announced that its immunogenicity testing technology is being highlighted by Bristol-Myers Squibb (“BMS”) in both a presentation and a case study at the 9th Workshop on Recent Issues in Bioanalysis in Miami, Florida (“9th WRIB”), from April 13th to 17th 2015.

The presentation will be given on April 17th by Renuka Pillutla, PhD, Director, Bioanalytical Sciences – Biologics for Bristol-Myers Squibb. The title of the talk is “Application of SQI Multiplex Platform in Immunogenicity Testing – Epitope Mapping and Isotyping.”

The case study featuring SQI’s next generation technology in immunogenicity testing will be led by Linlin Luo, PhD, Senior Research Investigator at Bristol-Myers Squibb on April 13th. The title of her talk is “Understanding the Impact of Immunogenicity: Assessment, Effects on Biotherapeutics and Strategy for Immunogenicity Testing.”

“SQI is excited to see its immunogenicity and epitope mapping products showcased at the 9th WRIB and looks forward to the industry’s enthusiastic reaction to the latest use by BMS of its Ig_plex technology for epitope mapping. The validation and market exposure gained from the presentation and case study by Bristol-Myers Squibb is important,” said Andrew Morris, CEO of SQI Diagnostics. “A number of highly regarded global pharmaceutical companies have conducted thorough due diligence on our next generation technology and reported positive outcomes of their testing to us. We believe that our technology provides industry-leading performance and benefits for the testing of multiple anti-drug antibody targets in a single test, significantly improving work-flow and reducing labor costs. SQI’s technologies enable drug developers to align their processes with the emerging regulatory guidelines surrounding immunogenicity testing worldwide.”

Epitope mapping is the study of immune response of individual “domains”, or pieces of a protein, allowing pharmaceutical and biotech companies the ability to target and pinpoint the part of the therapeutic protein that is creating an immune response within the patient’s body.

About SQI Diagnostics

SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company’s proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality.

For more information, please visit

Sales and Marketing Contact

Russ Peloquin
Vice President, Global Commercial Operations

Investor Relations Contact

Andrew Morris
Chief Executive Officer
416.674.9500 ext. 229

Lennie Ryer
Chief Financial Officer
416.674.9500 ext. 241

Forward-looking Information

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “believe”, “in the process”, “benefits”, “leading to”, “possible” “is subject to” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to: the ability of our patents to adequately protect our rights or permit us to gain or keep any competitive advantage; our ability to market and sell our novel multiplexing technologies and detection platforms; our ability to maintain any technical or product advantages; our ability to continue to market and sell our products; potential supply problems or price fluctuations with sole source or other third-party suppliers on which SQI is dependent; SQI’s ability to increase customer orders and manufacturing volumes; adverse changes in general economic conditions; impact of healthcare reform legislation; and, SQI’s ability to raise additional funds in the future on acceptable terms or at all. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, which filings can be found at Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.